• In December 2025, Halozyme Therapeutics announced a global collaboration and exclusive license agreement granting Takeda access to its ENHANZE drug delivery technology for use with vedolizumab (ENTYVIO) in inflammatory bowel disease, with Halozyme receiving an upfront payment, potential milestones, and low‑mid single digit royalties on combination product sales.
• This deal strengthens Halozyme’s position as an enabling drug‑delivery partner in chronic gastrointestinal diseases, adding another large, long‑duration royalty opportunity to its ENHANZE portfolio.
• We’ll now explore how granting Takeda exclusive ENHANZE access for ENTYVIO could influence Halozyme’s partnership‑driven growth narrative and risk profile.

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Halozyme Therapeutics Investment Narrative Recap

To own Halozyme, you need to believe ENHANZE can stay a preferred drug delivery solution as more biologics move to subcutaneous dosing, while regulatory and partner concentration risks remain manageable. The Takeda ENTYVIO deal reinforces the core royalty-driven story and broadens disease exposure, but it does not materially change the near term focus on execution with existing oncology and immunology partners or the ongoing patent and reimbursement overhangs that investors are already watching.

Among recent announcements, the November 2025 Merus collaboration on petosemtamab is especially relevant, as it underscores how Halozyme is extending ENHANZE into additional oncology indications alongside gastrointestinal and neurology uses. Together with Takeda’s ENTYVIO agreement, it highlights how the near term royalty catalyst still rests on getting more ENHANZE-enabled biologics into subcutaneous formats and scaling adoption across multiple partners and therapeutic areas.

However, while these partnerships broaden Halozyme’s royalty base, investors should also be aware of the growing patent and IP challenge risk...

Halozyme Therapeutics' narrative projects $2.0 billion revenue and $1.1 billion earnings by 2028. This requires 18.7% yearly revenue growth and an earnings increase of about $0.5 billion from $557.3 million.

Uncover how Halozyme Therapeutics' forecasts yield a $76.00 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Eight members of the Simply Wall St Community currently place Halozyme’s fair value between US$76 and about US$201, a very wide spread of opinions. As you weigh those views, remember that Halozyme’s dependence on a handful of large ENHANZE partnerships and evolving reimbursement rules could both widen outcomes for future royalty revenues and make it important to compare several different scenarios before forming a view.

Explore 8 other fair value estimates on Halozyme Therapeutics - why the stock might be worth over 2x more than the current price!

Build Your Own Halozyme Therapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Halozyme Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Halozyme Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Halozyme Therapeutics' overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 39 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.